{"schema_version":"secwatch.filing_event.v1","accession":"0001809519-24-000162","form_type":"8-K","ticker":"GDRX","cik":"0001809519","company_name":"GoodRx Holdings, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.604065+00:00","generated_at":"2026-05-31T11:09:26.841103+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"GoodRx reports Q2 2024 revenue $200.6M, net income $6.7M, adjusted EBITDA $65.4M","bullets":["Revenue and Adjusted Revenue of $200.6M for Q2 2024.","Net income of $6.7M (3.3% margin); Adjusted Net Income of $32.4M (16.1% margin).","Adjusted EBITDA of $65.4M (32.6% margin).","Net cash from operations $9.7M; over 7M consumers of prescription offerings.","Interim CEO Scott Wagner noted progress in retail/PBM partnerships and brand medication scaling."],"urls":{"canonical":"https://secwatch.observer/filing/0001809519-24-000162","json":"https://secwatch.observer/filing/0001809519-24-000162.json","markdown":"https://secwatch.observer/filing/0001809519-24-000162.md","text":"https://secwatch.observer/filing/0001809519-24-000162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000162/0001809519-24-000162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1809519/000180951924000162/gdrx-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:09:26.841103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}